There is quite an interest in expediting a BoM2 trial oldtimer, just no money to do anything about it.

It takes a strong management team to set a large trial off after failing a PIII trial. We did not reach our prestated goals in the BoM trial and, as many have mentioned on this platform our management has it's problems. 

The idea was to do a COVID trial with APB at a small cost, comparatively, have a significant share price increase and then do the BoM2 trial without significant dilution for existing shareholders. As we have found on more than one occasion achieving goals is not one of the hot spots of this managements abilities.

APB has the ability to be one of the most significant scientific achievements in Canadian history. In the right hands it could change life for the better for millions of people. It's now time to sell this company to an entity that has the ability and financial prowess to get this drug to market.

tada